Mayne Pharma maintains a conservative and manageable debt profile, with total debt levels reported around $28 million to $37 million (USD/AUD equivalents), resulting in a very healthy and low debt-to-equity ratio of approximately 10.5 percent. The company's prudent balance sheet management, combined with adequate total assets and ongoing operational cash flow adjustments, ensures that it retains sufficient financial flexibility to fund strategic investments, product commercialization, and working capital needs without facing excessive leverage risks.